drugset / Trial / NCT07168200

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

NCT07168200

Phase 3 Recruiting 720 enrolled Shanghai Shengdi Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).

Timeline

Start
2025-10-17
Primary completion
2028-04
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody
Background Carboplatin Small molecule
Background Cisplatin Other / unclassified
Background Paclitaxel Small molecule

Indications